{"organizations": [], "uuid": "381998225a98ab6ab3a8bc0d84e6d5753443731f", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180422.html", "section_title": "Archive News &amp; Video for Sunday, 22 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/fresenius-care-outlook/fresenius-medical-cuts-2018-sales-target-after-drug-dosage-shift-idUSASO0003N4", "country": "US", "domain_rank": 408, "title": "Fresenius Medical cuts 2018 sales target after drug dosage shift", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.68, "site_type": "news", "published": "2018-04-22T23:09:00.000+03:00", "replies_count": 0, "uuid": "381998225a98ab6ab3a8bc0d84e6d5753443731f"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/fresenius-care-outlook/fresenius-medical-cuts-2018-sales-target-after-drug-dosage-shift-idUSASO0003N4", "ord_in_thread": 0, "title": "Fresenius Medical cuts 2018 sales target after drug dosage shift", "locations": [], "entities": {"persons": [{"name": "victoria bryan", "sentiment": "none"}, {"name": "david evans", "sentiment": "none"}], "locations": [{"name": "berlin", "sentiment": "none"}, {"name": "united states", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "fresenius medical care", "sentiment": "negative"}, {"name": "fresenius medical", "sentiment": "negative"}]}, "highlightText": "", "language": "english", "persons": [], "text": "BERLIN, April 22 (Reuters) - German dialysis specialist Fresenius Medical Care cut its 2018 sales target after a reduction in the dosing of calcimimetic drugs in the United States.\nThe company said on Sunday it now expects sales to rise by 5-7 percent at constant currency, compared with a previous forecast for a rise of around 8 percent.\nIt confirmed a target for net income to rise by 13-15 percent at constant currency.\nReporting by Victoria Bryan, editing by David Evans\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-22T23:09:00.000+03:00", "crawled": "2018-04-23T22:21:41.021+03:00", "highlightTitle": ""}